Abstract. S100A4 protein is associated with Ca\(^{2+}\)-dependent regulation of intracellular activities and is significant in the invasion, growth and metastasis of cancer. In order to express rat S100A4 functionally and identify its biological activity following purification, an S100A4 gene fragment was optimized and fully synthesized via overlapping polymerase chain reaction. The gene was inserted into the prokaryotic expression vector, pBV220, with phage λPRP promoters following confirmation by DNA sequencing. The pBV220-S100A4 plasmid was constructed and transformed into Escherichia coli DH5α. Following temperature induction, rat S100A4 was overexpressed and the protein was observed to be located in the supernatant of the lysates, which was ~30-40% of the total protein within the host. The protein was isolated and purified by metal-chelate affinity chromatography. High purity protein (>98% purity) was obtained and in vitro western blot analysis identified that the recombinant S100A4 was able to bind to the antibody against wild-type S100A4. The bioactivity of the recombinant protein was detected via Transwell migration and invasion assays. The polyclonal antibody of rat S100A4 protein was prepared for rabbit immunization and exhibited similar efficacies when compared with commercial S100A4. Therefore, rat S100A4 was functionally expressed in E. coli; thus, the production of active recombinant S100A4 protein in E. coli may further aid with the investigation and application of S100A4.

Introduction

S100A4 protein, a polypeptide containing 101 amino acids with a molecular weight of 11.5 kDa, is associated with Ca\(^{2+}\)-dependent regulation of intra- and extracellular activities, such as protein phosphorylation, enzyme activity and cell motility (1-4). Previous studies into the roles of S100A4 have predominantly focused on the invasive growth and metastasis of cancer (5–7). The increased expression of S100A4 is correlated with breast, colorectal and gastric carcinoma, and it has been suggested that S100A4 may be used in the early diagnosis and prognosis of cancer as a complementary specific biomarker (8,9). However, problems such as preparation complexity and cross-reactivity of available antibodies impede further investigation into the biochemical roles and distribution of the S100A4 protein. Therefore, the possibility of generating whole S100A4 via recombinant techniques may be advantageous in such applications. In the present study, the construction and expression of a synthetic gene that encodes S100A4 within Escherichia coli, is described. The expressed S100A4 protein is highly soluble and stable, as well as functionally active. Thus, the present study provides a foundation for further investigation and for application of S100A4 in clinical studies.

Materials and methods

Reagents. Cloning vector pEasy-T3, vector pBV-220 and E. coli DH5α were preserved in the Performance Medicine Laboratory of the Institute of Health and Environmental Medicine (Tianjin, China). A gel extraction kit, plasmid extraction kit, BamH1, EcoR1 and T4 DNA ligase were purchased from Promega Corporation (Madison, WI, USA). Taq DNA polymerase and Pfu DNA polymerase were obtained from Tiangen Biotech (Beijing, China). Rat S100A4 multifunctional antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Acrylamide and N,N'-methylenebisacrylamide were purchased from GE Healthcare Life Sciences (Pittsburgh, PA, USA). SDS, 3,3'-diaminobenzidine tetrahydrochloride and staphylococcal...
protein A (SPA) sepharose CL-4B column chromatography equipment was procured from Sigma (St. Louis, MO, USA). All other chemicals were obtained from Shanghai Sangon Biological Engineering Technology and Service Co., Ltd. (Shanghai, China). Cell culture inserts were purchased from Millipore (Billerica, MA, USA) and 24-well cell culture plates were acquired from Corning Co., Ltd. (Corning, NY, USA). Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ, USA) and complete and incomplete Freund's adjuvant was obtained from Beijing Dingguo Biotechnology Co., Ltd. (Beijing, China). The remaining chemical reagents used in the experiments were of analytical grade.

This study was approved by the ethics committee of the Institute of Health and Environmental Medicine (Tianjin, China).

Construction of cloning vector pEasy-T3 S100A4. The gene fragment of rat S100A4 was constructed by overlapping polymerase chain reaction (PCR) using 12 synthetic oligonucleotides as primers (Table I). The primers were synthesized based on the codon preference within E. coli. The forward primer, pbfr104, 5'-GCTGAATTCAATGGCGGTCTCGGCTGGAAG-3' contained a site for EcoRI (underlined), whereas the reverse primer, pbfr104, 5'-GCAGGATCCATATATATGGATGTGATGATGC-3' contained a site for BamHI (underlined). Underlining denotes a stop codon.

Expression of rat recombinant S100A4 protein. The coding region of rat S100A4 in the cloning vector was digested by EcoRI and BamHI and was ligated into the pEasy-T3 vector. S100A4-pEasy plasmid was sequenced to verify the integrity of S100A4 (Invitrogen Life Technologies, Carlsbad, CA, USA).

Purification of rat recombinant S100A4. Metal-chelate affinity chromatography (5 ml HiTrap HP; GE Healthcare Life Sciences) was used to purify the rat recombinant S100A4 using the Amersham fast-protein liquid chromatography (FPLC) purification system (Harlow Scientific, Arlington, MA, USA). The supernatant was diluted five times with 1X binding buffer (containing 0.1 mol/l guanidinium hydro-
chloride) prior to filtering and the generated liquids were discarded after the column was balanced to the baseline, according to the manufacturer's instructions. Step gradient elution was subsequently conducted with the elution buffer and the recombinant proteins were collected and confirmed via SDS-PAGE.

**Western blot analysis.** The purified protein was transferred to a nitrocellulose membrane following SDS-PAGE, using a semi-dry electrophoretic transfer device (Jim-X Biotechnology Co., Ltd., Dalian, China). The membrane was blocked with 3% bovine serum albumin (BSA) in PBS containing 0.5% Tween-20 and was incubated with rabbit polyclonal antibody against rat S100A4 (Santa Cruz Biotechnology, Inc.) and horseradish peroxidase (HRP)-coupled goat anti-rabbit IgG secondary antibody (Abcam (Hong Kong) Ltd., Hong Kong, China).

**Protein assay.** The protein concentrations in the samples were determined using a Bradford protein assay kit (Sangon Biotech, Shanghai Co., Ltd., Shanghai, China) with BSA at the standard concentration (10).

**SDS-PAGE analysis.** SDS-PAGE analysis was performed under denaturing conditions using the method described by Laemmli (11). The concentrations of the stacking and resolving gels were 5 and 15%, respectively.

**Bioactivity of the recombinant protein.** Recombinant protein bioactivity was identified by Transwell migration and invasion assays (12). Transwell invasion chambers were coated with Matrigel and the assays were conducted according to the manufacturer's instructions. HeLa cells (1x10^5) with 50 µg/ml recombinant S100A4 protein were placed in the top chambers and served as the experimental group, while HeLa cells (1x10^5) without S100A4 protein were used as the control group. The cells were incubated for 24 h at 37°C and the motile cells at the top of each chamber were removed with cotton swabs. The cells at the bottom of each chamber were fixed with 0.1% glutaraldehyde for 30 min, rinsed briefly with PBS and stained with 0.2% crystal violet for 20 min. The chambers were washed thoroughly with PBS and the number of migrating cells or invasive cells was tallied using x200 magnification (Olympus CKX31, Olympus, Tokyo, Japan); the mean number of cells per chamber was also determined. The results were calculated as the migration/invasion rate relative to the parental control cells. Each experimental condition was duplicated and repeated three times.

**Polyclonal antibody preparation.** Antibodies against rat S100A4 protein were raised within New Zealand white rabbits obtained from the Experimental Animal Center of the Institute of Health and Environmental Medicine Research (Heping, China). The immunization procedure was implemented as follows: On day one, 200 µg purified antigen was mixed with an equal volume of complete Freund's adjuvant, which was multipoint injected subcutaneously into the back of each rabbit. The rabbits were then boosted subcutaneously four times with 200 µg recombinant protein in incomplete Freund's adjuvant at 10 day intervals. The antiserum was collected and determined 10 days subsequent to the last injection. Purification of rabbit IgG was performed according to the methods described by Moro et al (13) with minor modifications. The IgG fraction was purified by precipitation with 100% saturated (NH₄)₂SO₄ and by passing the IgG fraction through the SPA-sepharose CL-4b column chromatograph.

**Antibody titer determination.** Antiserum titers were examined using indirect ELISA. The wells of the polystyrene microtiter plates were coated with an antigen and, following overnight incubation at 4°C, the coated microtiter plates were blocked with BSA. The wells were incubated for 15 min in the dark at room temperature, with polyclonal antibodies against S100A4 with different deliquations (from 1:100 to 1:100,000) and HRP-conjugated goat anti-rabbit IgG (dilution, 1:3,000); the peroxidase substrate was tetramethyl benzidine. Following incubation, the reaction was stopped using 2 M H₂SO₄ and the absorbance at was measured at an OD of 450 nm, using a microplate reader (Multiskan MK3; Thermoscientific, Waltham, MA, USA).

**Statistical analysis.** All results are expressed as the means ± SD. Data were analyzed using SPSS version 17 (SPSS, Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Design, cloning and analysis of the S100A4 synthetic gene. The natural gene sequence (GenBank accession no. NM012618) was used as the template for designing and optimizing S100A4 according to the E. coli codon usage. Thirty-four rare codons of the natural gene were replaced with synonymous high-frequency codons in a synthetic gene that encodes S100A4. A 300-bp fragment was synthesized using three-step PCR (Fig. 1A). The PCR-synthesized sequence cloned into the pEasy-T3 vector was digested by EcoRI and BamHI, thereby producing the expected band size.

Construction of the expression vector, pBV220-S100A4. The pEasy-S100A4 plasmid was sequenced to verify the integrity of S100A4. Following confirmation by DNA sequencing and EcoRI and BamHI digestion, the S100A4 gene was successfully cloned into the expression vector, pBV220-S100A4. Agarose gel analysis of the digestion of pBV220 is shown in Fig. 1B.

Recombinant S100A4 protein expression. The pBV220-S100A4 plasmid was transferred into E. coli DH5α and was induced using heat shock. The 11.5 kDa S100A4 fusion protein was expressed at a high level, ~20-30% of the total protein of the cell, as analyzed by Total Lab 2.01 software (Newcastle, UK; Fig. 2A). The expected 11.5 kDa band was apparent in the supernatant and absent in the negative control (Lane 0; Fig. 2B). The SDS-PAGE analysis indicated that the S100A4 protein was expressed in a soluble form.

Recombinant S100A4 purification. The 6X His-tagged S100A4 protein was one-step purified by the Ni²⁺ affinity chromatography column using the FPLC purification system. The column was washed with 200 mmol/l imidazole gradient elution buffer at 3 ml/min and ~15 ml concentrated eluted fluid was obtained (Fig. 3). The SDS-PAGE analysis identified that the protein remained intact and the purity of the final S100A4 was 95% following desalination with HiTrap Desalting (GE Healthcare Life Sciences; Fig. 4B). The yielded purified recombinant protein was ~50 mg/l of the induced culture.

Western blot analysis of recombinant S100A4. The rabbit polyclonal antibody was capable of recognizing natural S100A4 and recombinant S100A4 protein, and the western blot analysis identified that the recombinant S100A4 was functionally expressed (Fig. 4A).
Migration and invasion of HeLa cells. The Transwell migration and invasion assays identified that the number of cells in the experimental group was greater than that of the control group (Fig. 5A-D), thus identifying that the recombinant protein was capable of improving the motility and invasiveness of cancer cells. A four-fold increase was observed in the number of migrating cells in the experimental group compared with the control group (P<0.05; Fig. 5E). The invasive ability of the HeLa cells in the experimental group was determined using the Matrigel invasion assay, which identified that the invasive ability of HeLa cells in the experimental group was three-fold greater than that of the control group (P<0.05; Fig. 5F). This therefore indicated that the recombinant protein levels promoted the motility and invasiveness of cancer cells.

Titer and specificity of polyclonal antibody. Following rabbit immunization with recombinant S100A4, the antiserum was purified by protein G affinity chromatography. The anti-S100A4 antibody concentration was 0.78 mg/ml and the antibody titer, determined using ELISA, was ~1:120,000 (Fig. 6A). The antiserum obtained was specific to the recombinant protein according to the western blot analysis (Fig. 6B).

Discussion

In the present study, a pBV220-S100A4 vector was successfully constructed based on an optimized S100A4 gene. The soluble S100A4 protein was expressed at an increased level following transferal of the constructed expression vector into E. coli DH5α and induction via heat shock. The purity of the S100A4 protein was improved following purification via revised Ni affinity chromatography. Additional proteins with similar structures that belong to the same protein family were
also obtained, such as S100A1 and S100B, using the same methodology. The present study identified that the expression system was efficient and stable (15).

It has been shown that the synthesis of a full-length gene may contribute to the expression DH5α in E. coli by the optimized gene (16,17). There was an initial attempt to synthesize the S100A4 gene by one-step PCR; however, following several cloning procedures, it was not continued as one or two frame-shift or lethal mutations occurred in the synthesized sequence. These mutations may have been a result of the mismatch between overlapping primers. Therefore, two short fragments were synthesized by PCR and subsequently used to obtain the full-length gene by performing an additional PCR. This process was conducted to reduce the mismatch by decreasing the quantity of overlapping primers, which was reasonable and aided synthesis of long DNA fragments via PCR.

Studies have shown that pET30a(+) was used as the expression vector of the S100A4 protein (17,18). However, we used plasmid pBV220 as the expression vector in our experiment. The results of the present study demonstrated that the soluble S100A4 protein was expressed at a high level and accounted for >20% of the total protein levels, which was greater than that observed in pET30a(+). Plasmid pBV220, which was constructed at the National Institute for Viral Disease Control and Prevention, is an efficient cloning and expression vector that is regularly used in China (Beijing, China) (14). The temperature, induced by P_αP, double promoters, controls the pBV220 plasmid. The gene was inserted into pBV220 and was highly expressed in E. coli DH5α, which exhibits rapid growth and reproduction, low nutrition requirements and is readily manipulated. E. coli DH5α is an optimal expression system for proteins that are capable of biological activity in vitro. The present study identified that soluble S100A4 protein was expressed at a high level and accounted for >20% of the total protein.

The present study also aimed to obtain increasingly purified S100A4 proteins. In the initial purification investigation, soluble S100A4 was not successfully combined with certain metal ions and the penetrating fluids contained numerous target proteins. This may be due to the inability of the 6X His tag to be fully exposed during the protein folding process. Therefore, the common Ni affinity chromatography method was revised and following the addition of 0.1 mol L−1 guanidine hydrochloride into the binding buffers, the binding capacity was significantly improved and the protein was further purified. Thus suggesting that guanidine hydrochloride, or other denaturing agents at an appropriate concentration, are capable of effectively improving the binding as a result of increased exposure of the His tag to the target protein.

The Transwell migration and invasion assays showed that the recombinant protein levels promoted the motility and invasiveness of the cancer cells. Antiserum was obtained from immunized rabbits using S100A4 as the immunogen; the polyclonal antibody obtained was identified as possessing highly specific and sensitive affinities to the protein.

As anti-S100A4 antiserum was able to bind as strongly to recombinant S100A4 as to natural S100A4, the basic biological activity of recombinant S100A4 was retained. Thus, the expression vector, pBV220-S100A4, was successfully constructed based on the 6X His-tagged N-terminal S100A4 gene. The 6X His-tagged recombinant pBV220-S100A4 protein was purified using revised Ni affinity chromatography. In conclusion, the production of the active recombinant S100A4 protein within E. coli may aid with further investigation and applications of S100A4.

Acknowledgements

The authors would like to acknowledge the financial support of the National Natural Science Foundation of China (grant nos. 81373108, 81202164 and 30971421) and the Tianjin Research Program of Application Foundation and Advanced Technology (grant no. 10JCYBJC10200).

References

1. Yammani RR, Long D and Locser RF: Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes. Arthritis Rheum 60: 792-800, 2009.
2. Ismail TM, Zhang S, Fernig DG, Gross S, et al: Self-association of calcium-binding protein S100A4 and metastasis. J Biol Chem 285: 914-922, 2010.
3. Chen M, Sinha M, Luxon BA, et al: Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/melanotransferin. J Biol Chem 284: 1484-1494, 2009.
4. Oslejšková L, Grigorian M, Hulejová H, et al: Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. Rheumatology (Oxford) 48: 1590-1594, 2009.
5. Xie R, Schlumbrecht MP, Shipley GL, et al: S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest 89: 937-947, 2009.
6. Sherbet GV: Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 280: 15-30, 2009.
7. Sack U and Stein U: Wnt up your mind - intervention strategies for S100A4-induced metastasis in colon cancer. Gen Physiol Biophys 28: F55-F64, 2009.
8. Boye K and Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176: 528-535, 2010.
9. Ai KX, Lu LY, Huang XY, et al: Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol 14: 1931-1935, 2008.
10. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
11. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
12. Gao XN, Tang SQ and Zhang XF: S100A4 antisense oligodeoxynucleotide suppresses invasive potential of neuroblastoma cells. J Pediatr Surg 40: 648-652, 2005.
13. Moro A, Yoshitake T, Ogawa T, et al: Single-step purification of pepsin-derived monoclonal antibody fragments from crude murine ascitic fluids by ceramic hydroxyapatite high-performance liquid chromatography. J Biochem 144: 733-739, 2008.
14. Tang X, Tan Y, Zhu H, et al: Microbial conversion of glycerol to 1,3-propanediol by an engineered strain of Escherichia coli. Appl Environ Microbiol 75: 1628-1634, 2009.
15. Liu ZQ, Chen YY, Wang TH, et al: Expression, purification, and identification of human S100A1 protein. J Prev Med Chin PLA 29: 240-244, 2011.
16. Han L, He HL, Guan WL, et al: Prokaryotic expression and purification of bioactive human S100A4. Genomics and Applied Biology 32: 142-148, 2013 (In Chinese).
17. Marlatt NM, Spratt DE, and Shaw GS: Codon optimization for enhanced Escherichia coli expression of human S100A1 and S100A4 proteins. Protein Expr Purif 73: 56-64, 2011.